INTRODUCTION
Gene fusion is one of the hallmark of cancer genome through chromosomal rearrangements triggered by DNA double-strand breakage. Accordingly, many fusion genes (FGs) have been identified as important biomarkers and therapeutic targets in multiple cancer types. Identification and analysis of fusion genes (FGs) will provide important insights into the mechanisms of cancer development and design novel therapeutic strategies (1) . With the exponential growth of cancer genomic and other biomedical data, several studies have integrated and searched fusion genes across multiple cancer types (e.g. pan-cancer studies). The improved database of chimeric transcripts and RNA-seq data (ChiTaRS 3.1) provided 20 131 human breakpoints from expressed sequence tags (EST) (2) . Since the TCGA database was open to the public, four research groups have been working on predicting FGs and tried to identify driver FGs from this dataset. Stransky et al. predicted fusion genes involving kinases across 20 cancer types from ∼7000 TCGA samples (3) . In this study, the authors filtered out the FGs that were also detected in normal samples of TCGA and the Genotype-Tissue Expression (GTEx) project. Their studies suggested that 3.0% of tumor samples contained likely oncogenic, recurrent kinase fusion genes. ChimerDB 3.0 has an enhanced coverage of fusion gene data through literature mining using machine learning method (4) and provided 30K FG pairs by analyzing RNA-seq data of 5300 TCGA samples across 28 cancer types. TumorFusions, an integrative resource for cancer-associated transcript fusions, predicted FGs from 9966 TCGA samples across 33 cancer types (5) . They applied stringent criteria and resulted in ∼21K FGs. Most recently, Gao et al. selected FGs called from at least two callers and predicted in ∼ 26K FGs from 9624 TCGA samples of 33 cancer types (6) .
Although above studies have provided a huge amount of reliable FGs, such resources did not present detailed functional annotation of individual FGs. In addition, the identification of driver FGs was solely based on the kinase FGs. So far, a systematic annotation of FGs in cancer regarding the retention of diverse functional domains and protein features, which are important in understanding cellular process and tumorigenesis, has not been available. In this study, we investigated the retention of 39 protein features of 43 895 FGs with ORF annotation and identified 331, 303, 840 and 667 in-frame FGs with retaining kinase domain, DNA-binding domain, oncogene domains, and epigenetic factor (epifactor) domains, respectively. Furthermore, we identified 896 and 118 in-frame FGs that did not retain their functional domains of tumor suppressor genes and DNA damage repair genes, respectively. In contrast, there were 6863 FGs with domain retention, but they lost their function due to the frame-shift ORF by chromosomal rearrangement. We also analyzed the retention information for protein-protein interaction (PPI) in fusion protein. Such analysis can provide fusion gene candidates who lose important interactions with cellular regulators. Through this analysis, we identified 718 and 976 FGs with PPI retention and without PPI retention, respectively. 761 FGs have no PPI functionalities due to ORF frameshifts. Since the identification and browsing of FGs for analysis and validation are based on the exact genomic breakpoints, obtaining accurate fusion transcript and fusion amino acid sequences are very important for further studies in both of the dry-and wet-lab, and are urgent needs for many cancer researchers. However, the exact fusion transcript or fusion amino acid sequences of all existing fusion genes considering multiple isoforms and breakpoints are not available. We have created these fusion sequences based on the genomic breakpoints at the Ensembl gene isoform structures (7) .
Here, we give a detailed introduction of the FusionGDB (Fusion Gene annotation DataBase), including the web interface and its applications. Our database includes features of all human FGs based on large cancer dataset analysis using systematic bioinformatics approaches, providing resources or references for functional annotation of fusion genes. FusionGDB will be a unique resource of cancer research for understanding the mechanisms of cancer development and identifying potential therapeutic targets against cancer.
DATABASE OVERVIEW
We first collected 48 117 FGs across pan-cancer from three representative fusion gene resources: the improved database of chimeric transcripts and RNA-seq data (ChiTaRS 3.1) (2), an integrative resource for cancerassociated transcript fusions (TumorFusions) (5) and The Cancer Genome Atlas (TCGA) fusions by Gao et al. (6) (Supplementary Table S1 ). For these ∼48K FGs, we performed functional annotations including gene assessment across pan-cancer fusion genes, open reading frame (ORF) assignment, and protein domain retention searches based on multiple isoform gene structures and breakpoints, and finally provided the fusion transcripts and amino acid sequences for each breakpoint and gene isoforms (Figure 1 and Supplementary Table S2 Table  S4 ). All of these information is included in the database and downloadable with unique and efficient data formats.
The main features of the FusionGDB annotations are summarized as follows. (i) The FusionGeneSummary category displays an overview of multiple annotations of fusion genes. Specifically, in this category, we added two genetic assessment scores, such as the Degree of Frequency (DoF) and the Major Active Isofusion Index (MAII), to provide the impact of each gene on pan-cancer gene fusions, which were created from previous studies (Supplementary  Table S5A and B (9, 10) . Figure 2 shows the top-ranked impact genes for the 5 -genes (Head genes or Hgenes) and 3 -genes (Tail genes or Tgenes) of pan-cancer FGs through our scoring system. Furthermore, this category also shows the assignment of functional classes of each fusion gene to help understand the tumorigenic mechanisms. (ii) FusionProtFeature category provides the retention information of 39 protein features of fusion proteins based on their multiple isoforms of gene structures and multiple breakpoints. Through focusing on the protein domains or regions of interest among the 39 features, users can understand more about the overall function of specific fusion genes and make a hypothesis/plan for further research on tumorigenesis. (iii) In the FusionGeneSequence category, we present full-length fusion transcript and coding region (CDS) sequences, and amino acid sequences based on the multiple breakpoints and matched gene isoforms. (iv) FusionGenePPI category provides protein-protein interaction (PPI) information of fusion proteins. This category also present a link to the chimeric protein-protein interaction (ChiPPI) (11) for users to get fusion domain networks. It also shows the list of interactors with each partner protein in wild-type to infer the original interactions. Specifically, this category provides retention annotations of PPIs for better understand the possible loss or gain of interactions with important cellular regulatory factors due to structural disruptions of gene fusion. (v) RelatedDrug and RelatedDisease categories are designed for providing FG related drugs and diseases. By using these two categories, we identified 1341 approved drugs for 1302 genes involved in 8423 FGs and 6169 genes associated with 4679 different types of diseases from DrugBank (12) and DisGeNet (13), respectively. The details of the data and analysis processes are described in the following section. Figure 1 and Table 1 website with a unique and efficient visualization interface (https://ccsm.uth.edu/FusionGDB).
DATA INTEGRATION AND ANNOTATIONS

Fusion gene information
We GRCh38 to GRCh37 using Batch Coordinate Conversion (liftOver) utility from UCSC Genome Browser (14) to fit with the reference genome of the other two resources. The following FG information from these resources have been collected: sample ID or expressed sequence tag (EST) ID, the name of fusion partner gene and exon junction breakpoint. We followed the definition of FGs direction for the Hgene (Head gene or 5 -gene) and Tgene (Tail gene or 3 -gene) to these datasets. ERG  ABL1  MAML3  KMT2A  RARA  AFF1  ARHGAP26  RET  TACC3  MERTK  ROS1  MYH11  LYZ  RAF1  NTRK3  TERT  WWOX  CHMP1A  TFE3  SIAE  PPP1R1B  PITPNC1  SMYD3  ALK  CCT5  RAD51B  GPHN  OS9  NARS2  BIRC6  SKAP1  NUP107  SND1  DSP  UVRAG  BRAF  VMP1 RARA  SS18  CCDC6  RUNX1  TMPRSS2  BCR  EWSR1  CBFB  KMT2A  COL1A1  MED1  KIF26B  HMGA2  KAT6A  KDM2A  EML4  ETV6  LTBP1  FBXL20  NFIX  MED24  ERBB2  BRAF  PDE4D  FGFR2  CREBBP  ACTN4  MDM2  TRIO  USP32  GNAS  ZMYND8  ERC1  FCHSD2  UVRAG  NCOR2  PARD3  FAF1  PUM1  PPFIA1  ROCK1  ARID1A  TBC1D22A  AGAP1  NF1  ACACA 
Manual curation of PubMed articles
Open reading frame (ORF) annotation
We examined the open reading frames of individual fusion transcript sequences between the 5 -and 3 -partner genes. When both of the breakpoints in 5 -and 3 -genes are located inside of coding region (CDS) and the number of fusion transcript sequences from the transcription start site of 5 -gene to transcription end site of 3 -gene is a multiple of three, then we reported such fusion genes as 'in-frame'. If there is one or two nucleotide insertions, then we reported such FGs as 'frame-shift'. Except these two types of ORFs, there are 15 more ORFs such as '3UTR-CDS', '3UTR-3UTR', '3UTR-5UTR', '3UTR-intron', 'CDS-3UTR', 'CDS-5UTR', 'CDS-intron', '5UTR-CDS', '5UTR-3UTR', '5UTR-5UTR', '5UTR-intron', 'intron-CDS', 'intron-3UTR', 'intron-5UTR' and 'intron-intron'. Here, the FGs are named 'intron', when the breakpoint is located 6bp apart from the exon junction site to the intron direction. Since our fusion breakpoints were derived from the ESTs and RNA-seq data, all the breakpoint should be located inside of the exon. Therefore, if the breakpoint is located on the intron in at least one of the partners, then we report it as 'intron'. These categories are marked as not available (NA) ORF cases in our ORF classification. To do so, we took all matched Ensembl transcripts (ENSTs) into consideration (7). 37 900 and 40 109 breakpoints of 11 873 and 13 771 partner genes were matched with 48 781 and 54 296 ENSTs for the 5 -and 3 -genes, respectively. Total 60 466 ENSTs were mapped to 15 555 genes involved in 43 895 FGs.
Retention analysis of 39 protein features from UniProt
We first downloaded the protein information in general feature format (GFF) of 15,025 accessions of UniProt for a total of 17 110 genes involved in 43 895 FGs (8) . UniProt provides the locus information of 39 protein features, including six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and three secondary structure features. Since such feature locus information are based on amino acid sequence, the genomic sequence of breakpoints was converted to the amino acid information for each kinase, for all protein accessions of UniProt, ENST isoforms and multiple breakpoints of each partner. To map each feature to the human genome sequence, we used the GENCODE gene model of the human reference genome (hg19v19) available from the Encyclope- dia of genes and gene variants (GENCODE) (15) . For the 5 -partner genes, if the breakpoints occur after the 3 end of the protein features, then the protein features are considered to be successfully retained in the fusion genes. On the contrary, if the kinase domain is not completely contained in the resultant FG, such fusion gene is thought to not retain its protein feature. Similarly, for 3 -partner gene, we considered the fusion genes to have retained protein features if the breakpoints appear on the 5 -end of the protein feature region. Table 1 shows the overall statistics of protein feature retention status for individual of 5 -and 3 -partner genes of FGs.
Creating fusion transcript and fusion amino acid sequences
Two different genes can form different FGs with multiple breakpoints based on multiple gene isoforms. Therefore, we considered all gene isoforms at each breakpoint. This study is designed to help users identify and validate FGs. Thus, we focused on the in-frame FGs. To obtain reliable FGs, we checked the distance between the two breakpoints in the case of intra-chromosomal rearrangements and created fusion sequences when these genes are apart more than 100 kb. We also selected FGs with both of their breakpoints aligned at the exon junction. To call each exon sequence of a given breakpoint, transcription start/end sites, and CDS start/end sites, we used the nibFrag utility of 
Protein-protein interaction information
We downloaded the interactor information from BI-OGRID (v 3.4.260) to provide PPI information for the wildtype proteins of individual fusion partners (16) . There are limitations of this dataset, such as providing only the names of the interactors. Since we need to know the locus information for each PPI to search the retention of the PPI at the fusion protein level, we recognized that the 'Region' feature is one of the 39 protein features provided by UniProt, which includes the start and end locus information on the structure of each wild-type protein for each PPI. Therefore, we followed the same approach for the protein feature retention screening here. During the protein feature retention search, we also checked whether the fusion proteins retain these interaction loci.
Functional or gene category assignment
To assign the functional or gene categories, we integrated cancer genes in our study, such as oncogenes, tumor suppressors, epigenetic regulators, DNA damage repair genes, kinases, and transcription factors. The first four types of genes were downloaded from CancerGenes, a gene selection resource for cancer genome projects (17); TSGene, an updated literature-based knowledgebase for tumor suppressor genes (18); EpiFactors, a comprehensive database of human epigenetic factors and complexes (17, 19) ; and the data from the studies by Knijnenburg et al. (20) . For the gene groups of kinases and transcription factors, we examined the genes with kinase domains or DNA-binding domains and protein features.
Drug and disease information
The drug-target interactions (DTIs) were extracted from the DrugBank (April 2018, version 5.1.0). The duplicated DTI pairs were excluded (12) . All drugs were grouped using the Anatomical Therapeutic Chemical (ATC) classification system codes. Disease-gene information was extracted from DisGeNet (June 2018, version 4.0) (13), a database of genedisease associations.
Database architecture
The FusionGDB system is based on a three-tier architecture: client, server and database. It includes a user-friendly web interface, Perl's DBI module, and MySQL database. This database was developed on the MySQL 3.23 with the MyISAM storage engine.
WEB INTERFACE AND ANALYSIS RESULTS
Fusion gene information category (FusionGeneSummary)
This category presents detailed information for both of partner genes and fusion genes ( Figure 3 ). For each partner gene, it shows the basic gene information with the Ensembl transcript accessions, including the breakpoints of fusion genes in their gene structures. This category also provides the gene impact assessment scores in pan-cancer fusion genes, including the Degree of Frequency (DoF) score and Major Active Isofusion Index (MAII) score from previous studies (9, 10) . It is hypothesized if a gene is involved in a fusion gene in multiple cancer types with multiple breakpoints and multiple partner genes, this gene will play a critical role in tumorigenesis. Based on this hypothesis, we defined the DoF score by multiplying three factors. Through dividing the number of fusion positive samples by the number of all possible combination of gene fusion (DoF score), we defined the impact of each isofusion (Supplementary  Table S5 ). Here, isofusion refers to a specific gene fusion combination with one specific partner gene and one specific breakpoint in a particular cancer type (MAII score finger'. All of the retention information for 39 features are available from the download page. ALK fusions are good examples of kinase domain retention in the fusion proteins. ALK is a transmembrane tyrosine kinase receptor. Wild-type ALK undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain upon ligand binding to its extracellular domain (22) . Up to date, ALK has been found to be rearranged, mutated, or amplified in a series of tumors, including anaplastic large cell lymphomas (ALCL), neuroblastoma, and non-small cell lung cancer (NSCLC). Chromosomal rearrangements are the most common alterations in ALK and result in genetic fusions, such as EML4-ALK, TFG-ALK, NPM1-ALK,] and SQSTM1-ALK (23) . Dimerization of fusion proteins leads to the constitutive activation of the kinase and transforming activity (24) . Table 2 shows the retention search results for the ALK fusion protein features provided in FusionProtFeature category. In all of these fusion genes, the 'Protein kinase' domain of ALK was retained, but the 'Extracellular' topological domain was lost. This explains the mechanism of constitutive activation of ALK kinase domain in fusion proteins. Through the systematic annotations of the functional characteristics of a protein in fusion proteins, the user can easily understand the possible roles of fusion genes in relation to their specific tumorigenesis.
Fusion transcript and amino acid sequence category (FusionGeneSequence)
This category provides the fusion sequences for transcripts and amino acids. The DNA level sequences are not included in this category since our fusion breakpoints are exon junction sites or inside of exons identified from the Sanger transcript sequences or RNA-seq reads. After filtering steps (see PPIE, PPP1R15A, KMT2A, ASH2L, HCFC1, HCFC2, MEN1, RBBP5, WDR5, AVP, INS, OXT, MAP3K5, HDAC1, CTBP1, CBX4, BMI1,  CREBBP, SMARCB1, CXXC1, MYB, CTNNB1, SNW1, E2F2, E2F4, E2F6, PSIP1, MLLT4, POLR2A, KAT8, RNF2, TP53, SBF1, MTM1,   SET, HIST1H3A, HIST1H4A, KAT6A, ELL, AFF1, AFF4, CDK9, CCNT1, CTR9, LEO1, PAF1, CDC73, WDR61, MLLT3, DOT1L, SKP2,  HIST3H3, SVIL, HIST2H3C, SIN3A, MLLT1, RUNX1, CBFB, H3F3A, SIRT7, ASB2, TCEB1, TCEB2, CBX8, TOP1, TAF6, NCL, HECW2, LGR4,  CSNK2A2, SENP3, SYMPK, PKN1, PIH1D1, KRAS, TAF1, CHD3, SMARCA2, SMARCC2, SMARCC1, HDAC2, RBBP4, RBBP7, TBP, MBD3,   SAP30, RAN, TAF9, TASP1, HIST1H2BG, EWSR1, DYNLT1, KIF11, ING4, ZNF131, ASB7   MLLT10  YEATS4, SMARCB1, SS18, MLLT10, DOT1L, MLLT1,  MLLT3, AFF1, DISC1, NDEL1, ELAVL1, CENPJ,  TMPO, ZNF526, MLLT6, TCP10L, In contrast, when we searched the fusion transcripts and amino acid sequences of the TMPRSS2-ERG fusion from the National Center for Biotechnology Information (NCBI), we were only able to obtain eight fusion transcript sequences and one fusion amino acid sequence (25) . Therefore, FusionGeneSequence category in FusionGDB can be used as an important reference or resource for the cancer and drug research communities.
Fusion protein-protein interaction information category (FusionGenePPI)
Protein-protein interaction (PPI) plays a crucial role in the cellular biological processes (26) . Specifically, studies have shown that the loss of PPI in the fusion genes leads to abnormal regulation of downstream genes. The well-known case is lysine methyltransferase 2A (MLL) fusion proteins. MLL translocations are associated with a wide array of hematologic malignancy and mutations in several family members are associated with cancer and developmental disorders (27) . Due to the truncation of the region of PPIs in the C-terminal MLL protein, MLL fusion proteins fail to retain the PHD finger region, the HCF1 interaction region and the SET domain region. As a result, MLL fusion proteins lose their ability to catalyze H3K4 methylation (28) . MLL1 and MLL2 function as large macromolecular complexes composed of >30 subunits, including several core components. One of the components, WD repeat domain 5 (WDR5) specifically recognizes histone H3 methylated at lysine (29) . Consequently, MLL regulated genes in down-stream showed different expressional regulation (30) . Through the FusionGenePPI category, in-silico evidence of these facts can be viewed. Firstly, this category shows the interactors at the wild type proteins for both of 5 -and 3 -partners as shown in Table 3A . The Table 3B and C provides the information of retained or lost PPIs in fusion proteins, respectively. As shown in Table 3C , MLL fusion proteins lose their interactions with histone H3K4me3 and WDR5, consistent with the previous studies. Therefore, our systematic investigation of PPI retention in fusion proteins will be very useful for understanding the genetic and epigenetic effect of fusion proteins in cancer.
Pharmacological information and disease information categories (FusionGeneDrug and FusionGeneDisease)
FusionGeneDrug category provides the pharmacological information associated with the genes involved in FGs from DrugBank (12 
DISCUSSION AND FUTURE DIRECTION
FusionGDB is the first database that systematically annotates the function of fusion genes across pan-cancer. To serve broad biomedical research communities, we will continuously update and curate FGs routinely by checking new fusion gene or fusion protein data. We have identified 331, 303, 840 and 667 in-frame FGs with retaining kinase domains, DNA-binding domains, oncogene domains, and epifactor domains, respectively, and 976 FGs with no retained PPIs. Their genomic relationships, interactions, association with other oncogenes, and downstream effects are important for studying their potential roles in tumorigenesis, as well as developing possible molecular targets. We will extend our current approaches to further investigate the clinically important FGs and address their acting mechanisms as described above in near future. The easy-to-use website provides multiple annotation results to researchers and facilitates comprehensive functional studies of FGs. Thus, FusionGDB will be a useful resource for many investigators in pathology, cancer genomics and precision medicine, drug and therapeutic research, among others.
